1. Evofem increased Phexxi net product sales 19% to $4.3 million for the first quarter of 2022 vs. fourth quarter 2021.2. Evofem reduced its selling and marketing costs by 49% and its total operating expense by 19%.3. Huge Short position!4. Evofem received confirmation three weeks ago from one of the largest Pharmacy Benefit Managers (PBMs) in the nation that they will add Phexxi to their national template formularies with no restrictions. PBMs are companies that manage prescription drug benefits on behalf of health insurers, Medicare Part D drug plans, large employers, and other payers. Three large PBMs — CVS, Express Scripts, and UnitedHealth's Optum — account for more than 70 percent of claims volume.5. Great news coming from the Affordable Care Act6. The U.S. Food and Drug Administration granted EVO100 (Phexxi) Fast Track designation for the prevention of both chlamydia and gonorrhea.
Continue Reading |